Post by
subaru1i on Mar 01, 2024 8:47am
Why would anyone 'want' to attend the AVCN conference
at the MaRs building in the first place WHEN it is only open to medical practitioners and researchers.
The MaRs building in Toronto is home to Johnson & Johnson (JLABS) where they have been doing cannabis based research and AVCN, according to Keith Strachan comment at end of CC quarters ago, a JLABS "spin off".
Well if J & J has AVCN as a cannabis based spin off then who does Pfizer have?
It's all blue and rock hard.
Comment by
Olaf123 on Mar 01, 2024 12:45pm
https://www.jazzpharma.com/science/gw-cannabinoid-platform/
Comment by
subaru1i on Mar 01, 2024 2:31pm
JAZZ does not have licensing rights to acid form of cannabinoids making them so far a "one hit wonder" or a "one pony show". NO comparison at all to LABS and their global pharma partner, both controlling a large pipeline of over 20 candidates. Sit tight and wait for Pfizer....and DEA first.
Comment by
Olaf123 on Mar 01, 2024 6:39pm
The patent that expires in 2026? A 6.7 billions $ shortcut to compete with labs and the new industry?